(Q33365804)

26 July 2017

title

The efficacy of epirubicin, cisplatin, uracil/tegafur, and leucovorin in patients with advanced biliary tract carcinoma (English)

1 reference

26 July 2017

1 reference

9

Yeul-Hong Kim

1 reference

26 July 2017

Kyong-Hwa Park

1

1 reference

26 July 2017

In-Keun Choi

2

1 reference

26 July 2017

Seok-Jin Kim

3

1 reference

26 July 2017

Sang-Chul Oh

4

1 reference

26 July 2017

Jae-Hong Seo

5

1 reference

26 July 2017

Chul-Won Choi

6

1 reference

26 July 2017

Byung-Soo Kim

7

1 reference

26 July 2017

Sang-Won Shin

8

1 reference

26 July 2017

Jun-Suk Kim

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

26 July 2017

1 reference

26 July 2017

volume

103

1 reference

26 July 2017

issue

11

1 reference

26 July 2017

page(s)

2338-2343

1 reference

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma: implications for adjuvant therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Biliary tract neoplasms: update 2003.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Eastern cooperative oncology group experience with chemotherapy for inoperable gallbladder and bile duct cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Effective treatment of advanced biliary tract carcinoma using 5-fluorouracil continuous infusion with cisplatin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Optimization of 5-fluorouracil (5-FU)/cisplatin combination chemotherapy with a new schedule of leucovorin, 5-FU and cisplatin (LV5FU2-P regimen) in patients with biliary tract carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Uracil-tegafur in gastric carcinoma: a comprehensive review.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Phase II study of cisplatin, epirubicin, and continuous-infusion 5-fluorouracil for advanced biliary tract cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

A phase II trial of tegafur-uracil plus leucovorin (LV) in the treatment of advanced biliary tract carcinomas

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Chemotherapy in the treatment of advanced gallbladder cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21041

7 January 2021

Identifiers

DOI

10.1002/CNCR.21041

1 reference

26 July 2017

1 reference